Brian Pereira - Kalvista Pharmaceuticals Director
| KALV Stock | USD 11.35 0.34 3.09% |
Director
Dr. Brian J. G. Pereira M.D. is Director of the company. Prior to his role at AMAG, Brian held senior roles at Tufts Medical Center including President and CEO of a Tufts Medical Center Physician Organization and interim COO. Brian is Chairman of the Board of Directors of Africa Healthcare Network and of NephroPlus Ltd. He has previously served on the Board of several private and public companies, was the Chairman of the Board of the HarvardMIT Biomedical Enterprise Program and President and Board member of the National Kidney Foundation. Brian is an Adjunct Professor of Medicine at Tufts University School of Medicine and has authored over 200 published scientific articles. He received his medical degree from St. John Medical College, MD and DM from the Post Graduate Institute, and MBA from Kellogg School of Management at Northwestern University. since 2019.
| Age | 58 |
| Tenure | 5 years |
| Professional Marks | MBA |
| Address | 55 Cambridge Parkway, Cambridge, MA, United States, 02142 |
| Phone | 857 999 0075 |
| Web | https://www.kalvista.com |
Kalvista Pharmaceuticals Management Efficiency
The company has return on total asset (ROA) of (0.425) % which means that it has lost $0.425 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.7933) %, meaning that it created substantial loss on money invested by shareholders. Kalvista Pharmaceuticals' management efficiency ratios could be used to measure how well Kalvista Pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities. At this time, Kalvista Pharmaceuticals' Return On Capital Employed is fairly stable compared to the past year. Return On Equity is likely to climb to 0.17 in 2024, despite the fact that Return On Tangible Assets are likely to grow to (1.03). At this time, Kalvista Pharmaceuticals' Total Assets are fairly stable compared to the past year. Non Current Assets Total is likely to climb to about 13.1 M in 2024, whereas Net Tangible Assets are likely to drop slightly above 40.9 M in 2024.Similar Executives
| Showing other executives | DIRECTOR Age | ||
| Henry Chen | Syndax Pharmaceuticals | 44 | |
| Santo Costa | Cytokinetics | 73 | |
| John Henderson | Cytokinetics | 73 | |
| Ryan Schulke | Cogent Biosciences | 33 | |
| Faheem Hasnain | Kura Oncology | 59 | |
| Renee Gala | Gossamer Bio | 46 | |
| Sandford Smith | Cytokinetics | 71 | |
| Jason Rhodes | Replimune Group | 47 | |
| Joshua Bilenker | Gossamer Bio | 46 | |
| Kristina Burow | Gossamer Bio | 44 | |
| Stephanie Okey | Crinetics Pharmaceuticals | 58 | |
| Luke Evnin | Syndax Pharmaceuticals | 52 | |
| Daniel Brauser | Cogent Biosciences | 34 | |
| Richard Shea | Syndax Pharmaceuticals | 63 | |
| Hilary Ackermann | Dyne TherapeuticsInc | 60 | |
| Yuezhou Ou | Dyne TherapeuticsInc | 67 | |
| Jie Fu | Dyne TherapeuticsInc | 39 | |
| Jinjun Cao | Dyne TherapeuticsInc | 57 | |
| Shuguang Liu | Dyne TherapeuticsInc | 49 | |
| Yunan Ren | Cogent Biosciences | 41 | |
| Stephen Kaldor | Crinetics Pharmaceuticals | 55 | |
Management Performance
| Return On Equity | -0.79 | ||||
| Return On Asset | -0.42 |
Kalvista Pharmaceuticals Leadership Team
Elected by the shareholders, the Kalvista Pharmaceuticals' board of directors comprises two types of representatives: Kalvista Pharmaceuticals inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Kalvista. The board's role is to monitor Kalvista Pharmaceuticals' management team and ensure that shareholders' interests are well served. Kalvista Pharmaceuticals' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Kalvista Pharmaceuticals' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Arnold Oronsky, Director | ||
| Jarrod Aldom, Vice Communications | ||
| Ryan Baker, Head Relations | ||
| Brian Pereira, Director | ||
| Richard Aldrich, Chairman of the Board | ||
| John McKune, VP Fin | ||
| Christopher Yea, Chief Development Officer | ||
| Edward Unkart, Independent Director | ||
| Andreas Maetzel, Senior Vice President Medical | ||
| Daniel Soland, Director | ||
| Stephen Donnelly, Director Secretary | ||
| Rachel Morten, Senior QA | ||
| Martin Edwards, Director | ||
| Nicole Sweeny, Chief Officer | ||
| Benjamin Palleiko, Chief President | ||
| Thomas MBA, CEO Director | ||
| Michael PharmD, Senior Development | ||
| Albert Cha, Independent Director | ||
| Joshua Resnick, Director | ||
| David Burke, IR Contact Officer | ||
| MD MBA, Chief Officer | ||
| Thomas Crockett, CEO, Director | ||
| Edward Feener, Chief Scientific Officer | ||
| Rajeev Shah, Director | ||
| Brian JD, General Counsel |
Kalvista Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Kalvista Pharmaceuticals a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.79 | ||||
| Return On Asset | -0.42 | ||||
| Current Valuation | 396.35 M | ||||
| Shares Outstanding | 42.19 M | ||||
| Shares Owned By Insiders | 1.14 % | ||||
| Shares Owned By Institutions | 93.70 % | ||||
| Number Of Shares Shorted | 5.82 M | ||||
| Price To Earning | (2.82) X | ||||
| Price To Book | 5.66 X | ||||
| Price To Sales | 107.42 X |
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Kalvista Pharmaceuticals in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Kalvista Pharmaceuticals' short interest history, or implied volatility extrapolated from Kalvista Pharmaceuticals options trading.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Kalvista Pharmaceuticals. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in bureau of economic analysis. For more information on how to buy Kalvista Stock please use our How to Invest in Kalvista Pharmaceuticals guide.You can also try the Fundamentals Comparison module to compare fundamentals across multiple equities to find investing opportunities.
Complementary Tools for Kalvista Stock analysis
When running Kalvista Pharmaceuticals' price analysis, check to measure Kalvista Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Kalvista Pharmaceuticals is operating at the current time. Most of Kalvista Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Kalvista Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Kalvista Pharmaceuticals' price. Additionally, you may evaluate how the addition of Kalvista Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
| Positions Ratings Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Stock Screener Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook. | |
| Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios | |
| Odds Of Bankruptcy Get analysis of equity chance of financial distress in the next 2 years | |
| My Watchlist Analysis Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like | |
| Efficient Frontier Plot and analyze your portfolio and positions against risk-return landscape of the market. | |
| Balance Of Power Check stock momentum by analyzing Balance Of Power indicator and other technical ratios | |
| Crypto Correlations Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins | |
| CEOs Directory Screen CEOs from public companies around the world |
Is Kalvista Pharmaceuticals' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Kalvista Pharmaceuticals. If investors know Kalvista will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Kalvista Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (3.12) | Revenue Per Share 0.214 | Quarterly Revenue Growth 0.307 | Return On Assets (0.42) | Return On Equity (0.79) |
The market value of Kalvista Pharmaceuticals is measured differently than its book value, which is the value of Kalvista that is recorded on the company's balance sheet. Investors also form their own opinion of Kalvista Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Kalvista Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Kalvista Pharmaceuticals' market value can be influenced by many factors that don't directly affect Kalvista Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Kalvista Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Kalvista Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Kalvista Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.